- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01706406
Group Psychoeducational Treatment for Women With Sexual Arousal Difficulties, Phase II (Group PED)
The purpose of this study is to pilot test and determine the efficacy of a psychoeducational intervention (PED) we recently piloted in a group format for women with acquired sexual arousal disorder (FSAD).
HYPOTHESES:
- - Compared to baseline measures, the PED will result in significant improvement in self-report measures of: (a) subjective sexual arousal; (b) perception of genital arousal/genital sensitivity; (c) orgasmic experience; (d) sexual desire; (e) sexual distress; (f) relationship satisfaction; (g) depressive symptoms; and (h) quality of life.
- - It is unknown what effect the PED will have on actual physiological sexual arousal.
- - The group format will be a feasible and cost-effective method of delivering empirically supported treatment to women with sexual arousal difficulties and will contribute towards meeting the needs for sexual health care for women on the clinic wait-list at the BC Centre for Sexual Medicine.
Study Overview
Status
Intervention / Treatment
Detailed Description
Sexual arousal difficulties are common among women, affecting approximately 22% of women between the ages of 18 and 59 (Laumann, Paik & Rosen, 1999). Although there are evidence-based psychological treatments available for women with orgasmic and pain disorders, there are currently no empirically-supported treatments for women with acquired Sexual Arousal Disorder (FSAD). Moreover, there have been numerous attempts to find evidence for a pharmacological agent effective at treating women's sexual arousal complaints; however, to date these studies have been inconclusive. Given the significant role that sexual health plays in quality of life, the fact that effective psychological treatments for women's sexual dysfunction are not widely available, and the fact that wait-lists to see health care professionals with expertise in the area of sexual dysfunction are often unwieldy, there is a need to establish brief, evidence-based approaches to treat women's acquired FSAD. Psychological therapy in a group format is a standard practice at the BC Centre for Sexual Medicine. However, in this study we would like to collect information from participants that would help us in determining the specific efficacy of the PED as well as identifying demographic or participant variables that might predict a positive response to the PED. Because we are using this information to determine the treatment's efficacy and because we will use this information as the basis for a publication, we deem this to be a research trial in which ethics review is necessary.
OBJECTIVES: We have recently developed and tested a new psychoeducational treatment (PED) for the treatment of FSAD due to early-stage gynecologic cancer treatment, and for healthy women with FSAD. Our data show this PED to significantly improve self-reported sexual desire, arousal, mood, relationship distress, and quality of life. We are currently testing the efficacy of this PED in a larger sample of cancer survivors with FSAD. The goal for this study is to determine the efficacy of the group PED for currently seeking treatment at the BC Centre for Sexual Medicine for FSAD. By using a waitlist control group, we can determine if any improvement in sexual function is due to treatment or the passage of time.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
British Columbia
-
Vancouver, British Columbia, Canada, V5Z 1M9
- UBC Sexual Health Lab, Vancouver Hospital
-
Vancouver,, British Columbia, Canada, V5Z 1C6
- BC Centre for Sexual Medicine
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- between the ages of 19 and 65
- currently seeking treatment at the BC Centre for Sexual Medicine
- meet clinical criteria for acquired Female Sexual Arousal Disorder (FSAD);
- be proficient in English and willing to take part in group sessions.
Exclusion Criteria:
- does not meet clinical criteria for acquired Female Sexual Arousal Disorder (FSAD)
- not currently Seeking seeking treatment at the BC Centre for Sexual Medicine
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: 1 treatment
Women randomized into the "treatment" group will undergo pre-treatment testing (questionnaires and physiological assessment)within 14 days of beginning treatment
|
four 1.5 hour long group psychoeducational sessions, spaced 2 weeks apart for a total of 8 weeks.
|
|
Other: 2 waitlist
Women randomized to the "waitlist" group will undergo initial testing (questionnaires and physiological testing) and receive no treatment until the next scheduled group (4 months).
They will undergo pretreatment testing and treatment on the same schedule as women in the "treatment" group.
|
four 1.5 hour long group psychoeducational sessions, spaced 2 weeks apart for a total of 8 weeks.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in physiological sexual arousal
Time Frame: Sexual arousal will be measured approximately one week pre-treatment and approxiately two weeks post-treatment
|
Sexual arousal will be measured physiologically with a Vaginal Photoplethysmograph (VPP).
The VPP measures vaginal pulse amplitude (VPA) which has been found to be a sensitive and specific measure of genital arousal (Laan & Everaerd, 1995).
|
Sexual arousal will be measured approximately one week pre-treatment and approxiately two weeks post-treatment
|
|
Long-term change in physiological sexual arousal
Time Frame: Sexual arousal will be assessed approximately one-week pre-treatment and approximately 6 months post treatment
|
Sexual arousal will be measured physiologically with a Vaginal Photoplethysmograph (VPP).
The VPP measures vaginal pulse amplitude (VPA) which has been found to be a sensitive and specific measure of genital arousal (Laan & Everaerd, 1995).
|
Sexual arousal will be assessed approximately one-week pre-treatment and approximately 6 months post treatment
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Subjective sexual arousal
Time Frame: Subjective sexual arousal will be assessed approximately one week pre-treatment, approximately two-weeks post-treatment and approximately 6-months post treatment
|
The Female Sexual Function Inventory (FSFI; Rosen et al. 2000) questionnaire will be used to measure subjective sexual arousal.
The FSFI a 19-item self-report questionnaire which assesses sexual function in women.
It covers six sexual domains: lubrication, arousal, desire, pain, orgasm and satisfaction.
|
Subjective sexual arousal will be assessed approximately one week pre-treatment, approximately two-weeks post-treatment and approximately 6-months post treatment
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Sexual Distress
Time Frame: Sexual distress will be assessed approximately one week pre-treatment, approximatley two weeks post-treatment and approximately 6-months post-treatment
|
Sexual distress will be measured with the Female Sexual Distress Scale (FSDS, Derogatis et al. 2002).
The FSDS is a 12-item self-report questionnaire assessing for sexuality related personal distress.
|
Sexual distress will be assessed approximately one week pre-treatment, approximatley two weeks post-treatment and approximately 6-months post-treatment
|
|
Mood
Time Frame: Mood will be assessed approximately one week pre-treatment, approximatley two weeks post-treatment and approximately 6-months post-treatment
|
Mood will be measured with the Beck Depression Inventory (BDI; Beck & Beamesderfer, 1974), a widely-used self-report questionnaire designed to assess the severity of depressive symptoms.
|
Mood will be assessed approximately one week pre-treatment, approximatley two weeks post-treatment and approximately 6-months post-treatment
|
Collaborators and Investigators
Sponsor
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
- C05-0400-II
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Low Female Sexual Arousal
-
Biozeus Biopharmaceutical S.A.RecruitingFemale Sexual Dysfunction | Female Sexual Arousal DisorderBrazil
-
Biozeus Biopharmaceutical S.A.Not yet recruitingFemale Sexual Arousal Disorder | Female Sexual Dysfunction (FSD)Brazil
-
Procare Health Iberia S.L.WithdrawnFemale Sexual Interest/Arousal DisorderSpain
-
Kern Pharma, S.L.Analysis and Research Network, S.LUnknownFemale Sexual Arousal DisorderSpain
-
University of Texas at AustinCompletedFemale Sexual Arousal DisorderUnited States
-
University of Texas at AustinCompletedFemale Sexual Arousal DisorderUnited States
-
Cedars-Sinai Medical CenterTerminatedFemale Sexual Arousal DisorderUnited States
-
Strategic Science & Technologies, LLCDaré Bioscience, Inc.RecruitingFemale Sexual Arousal DisorderUnited States
-
Pfizer's Upjohn has merged with Mylan to form Viatris...CompletedFemale Sexual Arousal DisorderAustralia, United States
-
University of British ColumbiaCompleted
Clinical Trials on Brief psychoeducational intervention for female sexual arousal disorder
-
Centre for Addiction and Mental HealthCompletedBorderline Personality Disorder | Suicide and Self-harmCanada